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Immune-non immune networks in intestinal inflammation
Abstract
The intestinal mucosa forms a primary barrier providing both barrier function and immediate effective
recognition of bacterial products invading the mucosa. This is of great importance for the prevention of
permanent and chronic inflammation as a reaction to the commensal intestinal flora and the multitude of
antigens present in the intestinal lumen. It is obvious that a tight network of specialized cell types and
intense cell-cell communication is required to maintain this function and coordinate immunological
reactions. Yet most publications are focused on unidirectional cause and effect-chains. Since a real
integrated view on the network of cellular functions is not available or at least incomplete bidirectional
immune cell interactions with epithelial cells, fibroblasts/myofibroblasts, adipocytes endothelial cells
and the nervous system are reviewed in this article. Networking is certainly mediated by different
effector pathways but limited resources are available to assemble a model of interactions in intestinal
inflammatory diseases. However, recent development of knowledge regarding unidirectional and
bidirectional effect-chains is exciting. Apart from the classical discrimination of immune cells (such as
neutrophils, macrophages, and cytotoxic T cells) and non immune cells (epithelial cells, fibroblasts,
adipocytes and endothelial cells) it became stunningly evident that not only the classical immune cells
have the ability to track down pathogens as most of the mentioned cell types express pathogen
recognition receptors (toll-like receptors, Nod2) and defense mechanisms (such as secretion of
defensin).
Immune-non immune networks in intestinal inflammation 
 
Martin Hausmann, PhD, Gerhard Rogler, MD, PhD 
 
Clinic for Gastroenterology and Hepatology, Department of Internal 
Medicine, University Hospital Zürich, Switzerland 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Address for correspondence: 
Gerhard Rogler, MD, PhD 
Clinic for Gastroenterology and Hepatology 
Department of Internal Medicine  
University Hospital Zürich 
Rämistrasse 100 
8091 Zürich 
Switzerland 
Phone: +41-44-255-9519 
Fax: +41-44-255-9497   
E-mail: gerhard.rogler@usz.ch 
 
 
 
 
 
 
 
 2 
Abstract 
The intestinal mucosa forms a primary barrier providing both barrier 
function and immediate effective recognition of bacterial products invading 
the mucosa. This is of great importance for the prevention of permanent 
and chronic inflammation as a reaction to the commensal intestinal flora 
and the multitude of antigens present in the intestinal lumen. It is obvious 
that a tight network of specialized cell types and intense cell-cell 
communication is required to maintain this function and coordinate 
immunological reactions. Yet most publications are focused on 
unidirectional cause and effect-chains. 
Since a real integrated view on the network of cellular functions is not 
available or at least incomplete bidirectional immune cell interactions with 
epithelial cells, fibroblasts/myofibroblasts, adipocytes endothelial cells 
and the nervous system are reviewed in this article. Networking is 
certainly mediated by different effector pathways but limited resources are 
available to assemble a model of interactions in intestinal inflammatory 
diseases. However, recent development of knowledge regarding 
unidirectional and bidirectional effect-chains is exciting. Apart from the 
classical discrimination of immune cells (such as neutrophils, 
macrophages, and cytotoxic T cells) and non immune cells (epithelial cells, 
fibroblasts, adipocytes and endothelial cells) it became stunningly evident 
that not only the classical immune cells have the ability to track down 
pathogens as most of the mentioned cell types express pathogen 
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recognition receptors (Toll-like receptors, Nod2) and defense mechanisms 
(such as secretion of defensin).  
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Introduction 
The intestinal mucosa is exposed to a myriad of microbial and food-
antigens, uncountable potential pathogens and even more non-pathogenic 
molecules. Due to its enormous surface area the barrier function of the 
intestinal mucosa may be as important as its functions in nutrient 
absorption [1]. As a part of the barrier function there need to be effective 
defense mechanisms when the barrier becomes locally leaky [2]. Local 
inflammation that is always present to some limited extend can be 
regarded as one component of the mucosal defense system [3]. It is 
obvious that those mechanisms initiating or limiting inflammation need to 
be tightly regulated as they themselves might alter the mechanical barrier 
function [3]. Therefore, regulatory networks need to exist that do not only 
involve proteins of one specific cell type such as epithelial cells or antigen 
presenting cells. There needs to be a tight network of cell-cell 
communication in addition. 
However, networks are hard to scientifically investigate [4]. Recent 
advances in computational modeling have provided us with some methods 
to gain new insights into effector and mediator networks. Nevertheless 
most scientific work and most publications are focused on uni- or rarely 
bidirectional cause and effect-chains. Effects of certain cytokines (cause) 
on specific target cells have been studied in details [4-9]. In in vitro 
systems the addition of a certain cell population (such as regulatory T-
cells) to another cell type (such as Th1 cells or NK cells) has been studied 
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also resulting in a logical one-way street of cellular interaction. It is very 
likely that in real life there is never a situation in which a cell type gets 
into contact with another cell type only causing unidirectional changes. By 
choosing the read out in those experiments we narrow the angle of view or 
even pre-determine what we will be able to see. 
Therefore, the description of immune-non immune networks in intestinal 
inflammation must have intrinsic limitations [3, 4, 10, 11]. We try to 
reconstruct networks from data that were focused on unidirectional cause 
and effect-chains. This reconstruction on networks never can reflect the 
complex networking taking place in reality as we have to focus on certain 
specific aspects of this networking without applying complex computer 
programs. 
A further problem of discussing immune-non immune networks in the 
intestinal mucosa is the characterized by the fact that it is increasingly 
unclear which cells can be regarded as cells of the immune system. 
Clearly T-cells, B-cells, monocytes, neutrophils and antigen presenting 
cells (APCs) are regarded as classical immune cells [12]. However, in 
recent years we realized that perhaps the most important part of the 
immunologic barrier in the intestinal mucosa is set up by the innate 
immune system with its pattern recognition receptors (PRRs) [3]. PRRs 
such as Nod2 certainly play a role in the pathogenesis of Crohn’s disease 
(CD) [6, 13]. However, they are expressed not only in classical immune 
cells such as APCs but also in Paneth cells and intestinal epithelial cells 
[1, 14]. Furthermore, fibroblasts and myofibroblasts express toll-like 
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receptors (TLRs) and are able to take part in an initial defense reaction 
which may also be regarded as part of the innate immune system [15, 16]. 
The only way to overcome this problem is to retreat to the classical 
definition of immune cells. 
According to the classical view of immune cell – non immune cell 
interaction activated immune cells, such as neutrophils, macrophages, 
and cytotoxic T cells are aggressors that attack and destroy nearby cells, 
either directly through physical contact or indirectly through the release of 
soluble factors such as reactive oxygen metabolites or cytotoxic proteins. 
This model implicates that non immune cells (according to this 
conservative view) behave as passive ‘‘bystanders,’’ waiting to be injured. 
Claudio Fiocchi summarized this view excellently saying “This simple 
unidirectional model is intuitive, answers the plead-for one cause-one 
effect relationship, and is convenient, since it is merely necessary to 
understand how mucosal immunity works to explain most types of 
intestinal inflammation. Unfortunately, this view is also likely to be too 
restrictive, naive and incorrect.” [4]. 
As outlined above it is evident that non-classical immune cells such as 
epithelial cells, mesenchymal cells, endothelial cells and nerve cells not 
only influence immune reaction but are an essential part of defense 
mechanism and barrier functions in the intestinal mucosa [3, 17, 18]. 
They regulate APC or T-cell activation and in the case of epithelial cells 
even are the first line of host response against pathogens by reaction to 
bacterial wall products such as muramyl dipeptide bound to wild type 
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Nod2 protein by secreting anti-bacterial peptides such as defensins [1, 3, 
18]. As a consequence of this multiplicity effects and actions in the 
mucosa, a networking model of cell-cell interactions during inflammation 
more closely reflects reality.  
Networking is mediated by different effector pathways. Direct cell-cell 
contacts usually are followed by protein-protein or more specific receptor-
ligand interactions. In addition there is a network of soluble mediators 
secreted by cells allowing distant communication. Most of those soluble 
mediators are able to induce or repress the secretion of others. Both 
systems of networking, the cell-cell contact and the mediator-based, 
interact with each other. Cell-cell contact may change the expression and 
secretion of a soluble mediator and soluble mediators induce upregulation 
or repression of cell surface molecules involved in cell-cell contacts such 
as tight junction proteins, integrins, receptor-ligands systems and 
adhesion molecules. Due to this complexity and the limited resources to 
model these complex interactions the information on cellular networking 
in intestinal inflammatory diseases, such as CD and ulcerative colitis (UC) 
are very limited.  
 
Epithelial cell – immune cell interactions 
Intestinal epithelial cells are in direct physical contact with at least two 
populations of immune cells. Between the epithelial cells are scattered 
intra epithelial lymphocytes and through the pores of the basement 
membrane APCs such as intestinal macrophages (IMACs) or dendritic cells 
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send cell protrusions for direct contact [2, 14, 19, 20]. The communication 
between intestinal epithelial cells and lymphocytes has been studied to 
some detail. On one hand immune functions can influence the function 
(absorption, barrier, defense) of epithelial cells on the other epithelial cells 
are able to present antigens to T-cells [21-24] (Figure 1). Normal intestinal 
epithelial cells are able to activate CD8+ suppressor T-cells [25]. This 
activation is restricted by the class Ib molecule CD1d [23, 24]. Receptors 
for those nonclassical MHC I molecules are NK receptors (NKR) that can 
be expressed not only by NK cells but also by TCR γδ and TCR αβ CD8+ 
cells. Depending on the NKR, MHC class I molecules can either positively 
or negatively regulate NK and T cell activity [24] (Figure 1). Therefore, it is 
likely that nonclassical MHC I molecules as well as MHC II molecules 
expressed on intestinal epithelial cells play a role in the regulation of the 
immune response facilitate cross-talk between epithelial cells and 
lymphocytes and serve as another  link between the innate and the 
adaptive immune system [24] (Figure 1).  
Epithelial cells secrete chemokines [26] and cytokines modulating immune 
cell functions in their vicinity upon chronic inflammation [14, 27, 28] or 
during acute bacterial infection [29] (Figure 1).  
An important example for a pathophysiologically relevant molecule 
connecting epithelial cell and immune cell functions is NOD2/CARD15 
[14] (Figure 1). Paneth cells and to a smaller extend colonic epithelial cells 
express PRRs, which was found to be the most important susceptibility 
gene for the development of CD. In addition to NOD2/CARD15 there are 
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more PRR and “innate” pathways by which commensal and pathogenic 
bacteria can directly interact with intestinal epithelial cells such as TLRs 
or NALPS. NODs and NALPS contain a C-terminal leucine-rich repeat 
domain able to sense a microbial motif, an intermediary nucleotide 
binding site essential for the oligomerization and signal transduction and 
a caspase-activating and recruitment domain (CARD). PRR induced signal 
transduction is frequently followed by nuclear factor-kappaB (NF-κB) 
activation. Mutations of NOD2/CARD15 as found in CD are associated 
with an impaired activation of NF-κB. This indicates that a reduced ability 
of epithelial cells to activate NF-κB in response to intestinal bacteria may 
trigger pathological immune responses (Figure 2). In addition this is an 
example for a pathophysiologically crucial interaction or networking 
between epithelial cells and antigen presenting cells maintaining effective 
innate immunity and supporting defense mechanisms. On the other hand 
cytokines derived from macrophages such as tumor necrosis factor (TNF) 
and interferon (IFN)-γ are able to induce the expression of NOD2/CARD15 
[30] (Figure 2). Activation of IMACs obviously can increase the alertness of 
intestinal epithelial cells for bacterial translocation of invasion. This 
interaction certainly makes sense from a teleological point of view: If the 
barrier function is impaired bacteria may invade and activate 
macrophages which then stimulate intestinal epithelial cells to pay more 
attention (Figure 2). 
Epithelial cells not only regulate lymphocyte or macrophage functions they 
also influence activity of intestinal myofibroblasts. Soluble galectin-3, a 
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leptin, was shown to be the strongest activator of primary intestinal 
myofibroblasts secreted by epithelial cells [31]. A tremendous increase in 
fibroblast interleukin (IL)-8 secretion (> 100 fold) was observed upon 
culture in epithelial cell-conditioned media. Depletion of galectin-3 from 
conditioned media by immunoprecipitation abolished this stimulatory 
effect indicating the important role of intestinal epithelial cells in 
regulating the activity of mesenchymal cells [31]. 
 
Fibroblast/Myofibroblast – immune cell interactions 
Mesenchymal cells such as fibroblasts, myofibroblasts or smooth muscle 
cells have been viewed as being mainly structural and being only relevant 
for the formation of extracellular matrix and a three dimensional field into 
which the immune cells come to play their game. However, in the 
meantime we know that they produce a number of mediators known to be 
important effectors during inflammation [32, 33]. They secrete growth 
factors such as granulocyte colony stimulating factor (G-CSF) and 
granulocyte-macrophage colony stimulating factor (GM-CSF) [32, 33],  IL-
1, IL-6 or IL-8 (2-6) or chemokines as for example RANTES or MCP-1 [32, 
34]. These mediators haven been shown to play an important role for the 
stimulation of immune cells and for the pathogenesis of intestinal bowel 
disease (IBD) [15, 34, 35]. Cytokine and chemokine secretion is 
upregulated by bacterial lipopolysaccharide (LPS) [33] or by contact with 
T-cells [36, 37] suggesting a role of mesenchymal cells during host 
defense.  
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An example for another important cell-communication molecule 
connecting immune and non-immune cells is CD40. CD40 is a 45-50 kD 
membrane glycoprotein of 277 amino acids. It was originally described as 
a functionally important B-cell surface molecule. The ligand for CD40, 
CD40L, is a 33-39D glycoprotein of 261 amino acids, which is a member 
of the TNF superfamily. CD40 is not only expressed by B-cells but by 
many other cell types such as APCs, endothelial cells, epithelial cells and 
fibroblasts [32]. CD40L is produced as a type II transmembrane protein 
and may be present on the cell surface as a heteromultimeric complex, 
composed of membrane-bound and soluble forms. Apart from its 33 kDa 
form two shorter versions of the protein (31 kDa and 18 kDa) exist as 
soluble proteins. The receptor, CD40, activates several second messenger 
systems, including protein-tyrosine kinases, phosphatidylinositol 3-
kinase, phospholipase Cγ2 and serine-threonine stress-activated protein 
kinases. These different pathways finally result in the activation of 
transcription factors such as NF-κB or NF-AT.  
A functional role of the CD40-CD40L system has been found in 
mesenchymal cells [32]. Ligation of CD40 on fibroblasts by CD40L is 
followed by NF-κB activation and subsequent secretion of NF-κB-
dependent cytokines. Importantly, not only soluble CD40L is able to 
stimulate cytokine secretion by human lamina propria (myo)fibroblasts 
but also direct cell-cell interaction with CD4+ T-cells expressing CD40L 
can induce cytokine secretion from these fibrobasts. This could be an 
important mechanism of immune cell- non immune cell interactions 
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connecting intestinal mesenchymal cell- with T-cell-functions. Among the 
molecules induced by CD40 ligation in mucosal (myo)fibroblasts are IL-8, 
which can attract neutrophiles and MCP-1, which attracts 
monocytes/macrophages and ICAM-1. It has been shown that activation 
of intestinal fibroblasts induces ICAM-1 surface expression [38, 39]. 
Increased ICAM-1 expression is followed by increased adhesiveness for T-
cells [38] which may play a role for the mucosal immune system.  
LPS stimulation of myofibroblasts was demonstrated to be involved in 
intestinal fibrosis [40] and disturbance of epithelial cell barrier function 
[41]. In addition, stimulation with cytokines alters the proliferative 
response of intestinal myofibroblasts [42-44] and alters the phenotype. .  
Recent finding further indicate that intestinal fibroblasts can also function 
as APCs: Powell and coworkers demonstrated that human colonic 
myofibroblasts express MHC class II molecules in situ and when cultured 
with low concentrations of IFN-γ in vitro [45] (Figure 1). In addition the 
colonic myofibroblasts expressed T-cell co-stimulatory molecules and were 
able to induce allogeneic CD4+ T cell activation in an MHC class II- and 
B7-dependent manner [45] (Figure 1). The cells further were able to 
process and present antigens to antigen-specific T cells [45]. As these 
intestinal myofibroblasts obviously not only express the necessary 
molecule repertoire to stimulate T-cell responses but also are practically 
able to do so in vitro they may well be able to influence immune responses 
in the colonic mucosa and may have an important function in the 
maintenance of mucosal tolerance [45] (Figure 1). 
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Intestinal myofibroblasts furthermore seem to be able to influence the rate 
of apoptosis of immune cells [46-48]. Thereby they might influence the 
balance between different T-cell subsets which could be another important 
influence factor on inflammation and the mucosal immune system. 
 
Adipocyte – immune cell interactions 
The adipose tissue has long been regarded as a passive type of connective 
tissue that stores energy as triglycerides and releases energy as free fatty 
acids. However, due to the wide variety of molecules expressed in and 
secreted by adipocytes, the total adipose tissue mass is currently being 
recognized as a real endocrine organ [49]. The term “adipocytokines” has 
been introduced for the highly active adipose tissue-derived cytokines, 
such as adiponectin, resistin, leptin, and others [50, 51]. Since adipose 
tissue hypertrophy is seen in CD, secretory factors specifically released 
from creeping fat could possibly be involved in the pathogenesis of CD. 
Charriere et al demonstrated that stroma-vascular cells from adipose 
tissue or 3T3-L1 preadipocytes can transdifferentiate to macrophages and 
acquire phagocytic activity [52]. Since the creeping fat in CD is infiltrated 
by significant amounts of macrophages, the cellular compartment of 
macrophages residing within the mesenteric adipose tissue has gained 
attention. Xu et al. [53] and Weisberg et al. [54, 55] reported that adipose 
tissue is infiltrated by macrophages (but not lymphocytes or granulocytes) 
and that inflammatory cytokines are produced mainly by adipose-tissue 
homed macrophages rather than by adipocytes. It has been estimated that 
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the percentage of macrophages in adipose tissue ranges from < 10 % up to 
> 50 % [56, 57] suggesting a high cellular plasticity of the adipose tissue.  
Whereas Desreumaux et al. could not detect IL-1, IL-6 and IL-8 mRNA in 
mesenteric adipose tissue in CD [58], an increased mRNA expression of 
TNF [58]; leptin [59], or PPARγ  [60] has been demonstrated.  
Moreover, mesenteric but not subcutaneous adipocytes have been shown 
to produce high amounts of active cortisol due to specific expression of 
11β-hydroxysteroid-dehydrogenase type 1.  
Investigation of the cytokine repertoire of mesenterial adipocytes 
demonstrated a significant upregulation of the secretion of adiponectin 
and macrophage colony stimulating factor, as well as leptin and migration 
inhibitory factor, in CD compared cells from normal mucosa or 
diverticulitis [61]. Resistin, interleukin-6, and monocyte chemotactic 
protein-1 were not specifically induced in CD but were associated with 
unspecific inflammation [61].  
 
Endothelial cell – immune cell interactions 
Without endothelial cell – immune cell interactions no inflammation could 
take place in the intestinal mucosa. It is clear that leukocytes that are 
attracted to the intestinal mucosa and that want to leave the blood stream 
and evade from the vessel and capillaries first have to interact with 
endothelial cells. Several important factors influencing endothelial 
leukocyte interaction are well characterized. They apply not only to 
mucosal physiology or pathophysiology but are general principles of 
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inflammation. Very important molecules for this interaction are cell 
adhesion molecules expressed on the cell membranes of both cell types. 
One of the key cell adhesion molecules involved into the evasion program 
in the gut mucosa is the mucosal vascular addressin MAd-CAM-1, a 
receptor for the α4β7-integrin present on circulating lymphocytes and 
proposed to mediate their selective migration to the gut [62-64].  
In addition, there is evidence that reciprocal signaling between endothelial 
cells and leukocytes also involves cytokines produced by and acting on 
both cells. Soluble mediators may increase leukocyte adhesiveness to 
vascular endothelium as IL-1 does for polymorphonuclear cells and 
monocytes [65] and IL-4 does for T cells, but not for neutrophils [66].  
 
Nervous system – immune cell interactions  
The nervous system may be primarily understood as a network because 
the intestinal mucosa and submucosa is literally netlike and densely 
innervated by sympathetic and sensory nerve fibers. Nerval networking 
provides signal transfer in both directions. Input is the stimulation of 
sensory nerve fibres by cytokines [67, 68]. Output is mediated by the 
sympathetic and parasympathetic nervous system and is indeed 
multifunctional. Viability of intestinal lymphocytes is affected by 
epinephrine and norepinephrine [69]. Norepinephrine has been shown to 
inhibit immune functions such as phagocytosis, natural killer cell activity 
MHC class II expression, secretion of TNF, IL-12 and IFN-γ from 
macrophages or lymphocytes [70, 71]. The neuropeptide substance P (SP) 
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modulates epithelial cell restitution [72]. SP induced epithelial cell 
migration depends on a TGF-beta release from SP-stimulated fibroblasts 
as shown in vitro by Felderbauer et al [73].  
SP is one of the key molecules, a soluble factor representing a major 
immunregulatory circuit. SP is released from both nerves (enteric and 
sensory) and inflammatory cells (macrophages) [72, 74]. The according 
receptor (neurokinin-1 receptor, NK-1R) is expressed again on both nerves 
and inflammatory cells (macrophages, mast cells, T cells and epithelial 
cells [75, 76]). Further, human mesenteric preadipocytes participate in 
intestinal inflammatory responses via NK-1R related pathways [77].  
SP binding activates the NF-κB system in target cells leading to increased 
expression of NF-κB-driven proinflammatory genes. Mediator-based 
communication between nerves and immune cells at intestinal sites have 
mentioned to be associated with intestinal inflammation. Studies with 
animal models [78-80] strongly suggest a functional role for SP and NK-1R 
in IBD. Experimental colitis can be significantly suppressed with several 
NK-1R antagonists [81, 82]. In the pathophysiology of IBD increased SP 
expression has been observed in the tissue of patients with UC [83]. In UC 
SP positive nerve fibres sprout into the inflamed tissue [84, 85]. However, 
contradictory results have also been produced correlating density of SP 
immunreactive nerves and disease activity in UC patients or comparing 
mucosal SP levels between CD and control patients [85]. NK-1R 
antagonists are currently used as treatment of chemotherapy-induced 
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emesis and rheumatoid arthritis. Their potential benefit in IBD treatment 
remains to be elucidated.  
 
Conclusions 
Immune-non immune networks certainly play a very important role for 
innate and adaptive immune function of the intestinal mucosa and 
subsequently for intestinal inflammation. We are just at the beginning of 
understanding this network. Recent years have provided us with new 
insights into functions of mucosal cell types indicating that the classical 
definitions of immune and non-immune cells are no longer valid. Antigen 
presentation by non-classical immune cells or bacterial recognitions 
receptors in epithelial cells or fibroblasts may be just examples. It will be 
important to evaluate the complex networking of the specific cell types of 
the intestinal mucosa by computational analysis in the future. 
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Figure legends 
 
Figure 1 
“Classical” antigen presenting cells such as dendritic cells (DCs) and 
intestinal macrophages (IMACs) are present in the intestinal mucosa. 
However, they undergo a tissue specific differentiation. Due to their loss of 
co-stimulatory molecules they present antigens but induce tolerance 
during the absence of inflammation. During inflammatory conditions they 
are able to induce T-cell expansion and responses. Non-classical antigen 
presenting cells such as intestinal epithelial cells and fibroblast are also 
suited to induce tolerance or immune responses according to their 
molecular repertoire. The impact of either classical or non-classical 
immune cells on the balance of tolerance and inflammation is unclear and 
has to be elucidated. 
 
Figure 2 
The regulation of NOD2 expression and the associated innate immune 
responses are a typical example for cellular networking of immune and 
non-immune cells in the intestinal mucosa. If bacterial translocation 
occurs NOD2 action in IMACs may lead to NF-κB activation and induction 
of IFN-γ and TNF secretion. These cytokines upregulate NOD2 expression 
in epithelial cells which may allow increased defensin expression but also 
increased production of chemokines such as MCP-1. Increased MCP-1 
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secretion by epithelial cells will attract more IMACs and monocytes to the 
site of antigen entry which will induce IMACs driven defense responses 
such as secretion of reactive oxygen species (ROS, “oxidative burst 
reaction”) and induction of local inflammation. 
 
 
 
 
